NVCRNovoCure Limited
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+10% of shares).
Choppy, but holding above its 200-day average. Oversold (RSI 25). Price is +0% vs its 200-day average.
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How NVCR is trading
NovoCure Limited is +15% over the past year while the S&P 500 is +18%: 3.4 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +0.31%
vs 200-day average · close to trend
- RSI (14)
- 25
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 27%
Below its 52-week high
Details›
- Last close2026-10-09
- $14.58
- 1 monthS&P 500 +2.7%
- −5.0%
- 1 yearS&P 500 +18%
- +15%
- 5 yearsS&P 500 +88%
- −88%
- vs 50-day average$16.50
- −12%
- 52-week high
- $20.00
- 52-week low
- $10.03
- Annualised volatility
- 79%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$940K
| Year | Return |
|---|---|
| 2026 (year to date) | +13% |
| 2025 | −57% |
| 2024 | +100% |
| 2023 | −80% |
| 2022 | −2.3% |
| 2021 | −57% |
| 2020 | +105% |
| 2019 | +152% |
| 2018 | +66% |
| 2017 | +157% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 3 of 10 | +1.5% |
| Feb | 10 | 5 of 10 | +0.44% |
| Mar | 10 | 4 of 10 | −6.2% |
| Apr | 10 | 6 of 10 | +13% |
| May | 10 | 9 of 10 | +16% |
| Jun | 10 | 3 of 10 | −4.3% |
| Jul | 11 | 6 of 11 | +0.34% |
| Aug | 11 | 7 of 11 | +2.6% |
| Sep | 11 | 4 of 11 | −2.8% |
| Oct | 11 | 2 of 11 | −9.1% |
| Nov | 10 | 6 of 10 | +7.7% |
| Dec | 10 | 6 of 10 | +8.0% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.